| From: |
Elisabeth Szerencsics [ profile ] |
| Subject: |
UNAIDS/WHO Press Statement: Results
|
| Sent: |
Jul 14th, 2011 - 03:47:54 |
| Attachments: |
20110713_PS_Prep_en.pdf
|
|
| |
FYI
---------- Forwarded message ----------
From: JIM PICKETT
Date: 2011/7/13
Subject: [RectalMicro IRMA] UNAIDS and WHO hail new results showing
that
a once-daily pill for HIV-negative people can prevent them from
acquiring HIV - UNAIDS/WHO Press Statement - 13 July 2011
To: "RECTALMICRO (at) CRITPATH.ORG [2]"
-------------------------
Dear Colleagues,
Please find below and attached a joint UNAIDS/WHO press statement
hailing new results released today which show that a daily
antiretroviral tablet taken by people who do not have HIV infection can
reduce their risk of acquiring HIV by up to 73%.
The technical focal point is Cate Hankins, UNAIDS’ Chief Scientific
Advisor, hankinsc (at) unaids.org [4]
Best regards,
UNAIDS Communication team
PRESS STATEMENT
UNAIDS AND WHO HAIL NEW RESULTS SHOWING THAT A ONCE-DAILY PILL FOR
HIV-NEGATIVE PEOPLE CAN PREVENT THEM FROM ACQUIRING HIV
_New data from studies in Kenya, Uganda and Botswana confirm major role
of antiretroviral medicine in preventing heterosexual HIV transmission_
GENEVA, 13 JULY 2011—Results announced today from two studies reveal
that a daily antiretroviral tablet taken by people who do not have HIV
infection can reduce their risk of acquiring HIV by up to 73%. Both
daily tenofovir and daily tenofovir/emtricitabine taken as preventive
medicine (PrEP - pre-exposure prophylaxis) can prevent heterosexual
transmission of HIV from men to women and from women to men.
The Partners PrEP trial, conducted by the University of Washington’s
International Clinical Research Center, followed 4758 sero-discordant
couples (in which one person had HIV infection and the other did not)
in
Kenya and Uganda. Couples received counselling and free male and female
condoms. The uninfected partner took a once-daily tenofovir tablet or a
tenofovir/emtricitabine tablet or a placebo pill. There were 62% fewer
HIV infections in the group receiving tenofovir and 73% fewer HIV
infections in the group that took tenofovir /emtricitabine than in the
group receiving the placebo.
The TDF2 trial, conducted by the United States Centers for Disease
Control, followed 1200 men and women in Botswana who received either a
once-daily tenofovir/emtricitabine tablet or a placebo pill. The
antiretroviral tablet reduced the risk of acquiring HIV infection by
roughly 63% overall in the study population of uninfected heterosexual
men and women.
“This is a major scientific breakthrough which re-confirms the
essential role that antiretroviral medicine has to play in the AIDS
response,” said Michel Sidibé, Executive Director of the Joint United
Nations Programme on HIV/AIDS (UNAIDS). “These studies could help us
to reach the tipping point in the HIV epidemic.”
The medicines are available generically in many countries at prices as
low as US$ 0.25 per tablet. In November 2010, the iPrEx trial among men
who have sex with men in six countries reported a 44% reduction in HIV
transmission among those who took a daily tenofovir/emtricitabine
tablet.
"Effective new HIV prevention tools are urgently needed, and these
studies could have enormous impact in preventing heterosexual
transmission," said Dr Margaret Chan, WHO's Director-General. "WHO will
be working with countries to use the new findings to protect more men
and women from HIV infection."
UNAIDS and WHO have already been working with countries in sub-Saharan
Africa, Latin America and Asia to explore the potential role of
pre-exposure prophylaxis in HIV prevention. This news will encourage
more people to get tested for HIV, discuss HIV prevention options with
their partners and access essential HIV services.
It is currently estimated that only about half of the 33 million
people
living with HIV know their HIV status. An increase in the uptake of
testing for HIV would have a significant impact on the AIDS response,
particularly if more people gain access to new HIV prevention
technologies in light of the new findings.
UNAIDS and WHO recommend that individuals and couples make
evidence-informed decisions on which combination of HIV prevention
options is best for them. No single method is fully protective against
HIV. Antiretroviral drugs for prevention need to be combined with other
HIV prevention options. These include correct and consistent use of
male
and female condoms, waiting longer before having sex for the first
time,
having fewer partners, medical male circumcision and avoiding
penetrative sex.
[END]
CONTACT
UNAIDS Geneva | Sophie Barton-Knott | tel. +41 22 791 1697 |
bartonknotts (at) unaids.org [5]
UNAIDS
UNAIDS, the Joint United Nations Programme on HIV/AIDS, is an
innovative United Nations partnership that leads and inspires the world
in achieving universal access to HIV prevention, treatment, care and
support. Learn more at unaids.org [6].
_ _
--
You received this message because you are subscribed to the Google
Groups "Global AIDS Roundtable" group.
To post to this group, send email to
global-aids-roundtable (at) googlegroups.com [7].
To unsubscribe from this group, send email to
global-aids-roundtable+unsubscribe (at) googlegroups.com [8].
For more options, visit this group at
http://groups.google.com/group/global-aids-roundtable?hl=en [9].
_______________________________________________
Rectalmicro mailing list
Rectalmicro (at) lists.critpath.org [10]
https://lists.critpath.org/mailman/listinfo/rectalmicro [11]
Visit IRMA's website at www.rectalmicrobicides.org [12]
Links:
------
[1] mailto:JPickett (at) aidschicago.org
[2] mailto:RECTALMICRO (at) CRITPATH.ORG
[3] mailto:RECTALMICRO (at) lists.critpath.org
[4] mailto:hankinsc (at) unaids.org
[5] mailto:bartonknotts (at) unaids.org
[6] http://unaids.org
[7] mailto:global-aids-roundtable (at) googlegroups.com
[8] mailto:global-aids-roundtable%2Bunsubscribe (at) googlegroups.com
[9] http://groups.google.com/group/global-aids-roundtable?hl=en
[10] mailto:Rectalmicro (at) lists.critpath.org
[11] https://lists.critpath.org/mailman/listinfo/rectalmicro
[12] http://www.rectalmicrobicides.org
--
Elisabeth Szerencsics
Projektmanagement
ProMinus- Verein zur Auflärung über sexuelle Rechte und Gesundheit
National Focal Point
Global Youth Coalition on HIV/AIDS
Austria/Österreich
elisabeth.szerencsics (at) prominus.at Mobile: +43 650 8209338
www.prominus.at www.gyca.org
|
|
Message
back to messages
